---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-188090"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2023-07-17T23:59:59+00:00"
generated_at: "2026-06-13T07:30:48.324297+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 23 special meeting

## Summary
- MEI mailed letter to shareholders on July 17, 2023, pleading vote FOR the Infinity (INFI) merger at the July 23 special meeting.
- Combined company would hold three clinical-stage assets: Eganelisib, Voruciclib, ME-344 with data catalysts in 6-24 months.
- ISS and Glass Lewis both recommend FOR; ISS reiterated its support as recently as July 14, 2023.
- MEI claims the deal creates a well-capitalized pipeline and leverages the clinical expertise of both teams.

## SEC filing metadata
- accession: 0001193125-23-188090
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2023-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000119312523188090/0001193125-23-188090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000119312523188090/d536977d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-188090
- JSON: https://secwatch.observer/filing/0001193125-23-188090.json
- Plain text: https://secwatch.observer/filing/0001193125-23-188090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.